Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: Novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea

Antiviral Research

Volumn 56, Issue 2, 2002, Pages 167-181

  Mayhew, Christopher N ^a,b   Mampuru, Leseilane J ^c   Chendil, Damodoran ^a   Ahmed, Mansoor M ^a   Phillips, Jonathan D ^b   Greenberg, Richard N ^a   Elford, Howard L ^d   Gallicchio, Vincent S ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^c UNIVERSITY OF LIMPOPO   (South Africa)

^d Molecules for Health Inc   (United States)

Author keywords

Bone marrow toxicity; Didox; Hydroxyurea; Murine AIDS; Ribonucleotide reductase; Trimidox

Indexed keywords

3,4 DIHYDROXYBENZOHYDROXAMIC ACID; 3,4,5 TRIHYDROXYBENZOHYDROXAMIDOXIME; ANTIVIRUS AGENT; HYDROXYUREA; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BURST FORMING UNIT E; COLONY FORMING UNIT GM; CONTROLLED STUDY; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; FEMUR; HEMATOCRIT; HEMATOPOIETIC CELL; HYPERGAMMAGLOBULINEMIA; LEUKOCYTE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RETICULOCYTE COUNT; RETROVIRUS; RODENT DISEASE; SPLEEN; SPLENOMEGALY;

ANIMALS; BENZAMIDINES; BONE MARROW CELLS; DNA, VIRAL; FEMALE; FEMUR; FREE RADICAL SCAVENGERS; HEMATOPOIETIC STEM CELLS; HYDROXAMIC ACIDS; HYDROXYUREA; HYPERGAMMAGLOBULINEMIA; LEUKEMIA VIRUS, MURINE; LEUKEMIA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MURINE ACQUIRED IMMUNODEFICIENCY SYNDROME; PROVIRUSES; RETROVIRIDAE INFECTIONS; RIBONUCLEOTIDE REDUCTASES; SPLEEN; SPLENOMEGALY; TUMOR VIRUS INFECTIONS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; UNIDENTIFIED RETROVIRUS;

EID: 0036842228     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00108-0     Document Type: Article

References (41)

1. Biron F., Ponceau B., Bouhour D., Boibieux A., Verrier B., Peyramond D. Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 25:2000;329-336.
2. Broud D., Piper J., Gallicchio V., Black P., Kunder S., Goldberg H., Elford H., Hall B., van't Riet B., Bacho M., Mayhew C., Papermaster S., Oakley O., Ussery M. Novel ribonucleotide reductase (RR) inhibitors, didox and trimidox, produce antiretroviral effects in the murine acquired immunodeficiency (MAIDS) and in the HIV-infected HuPBMC SCID models. Antiviral Res. 37:1998;A58. (Abstract).
3. De Antoni A., Foli A., Lisziewicz J., Lori F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J. Infect. Dis. 176:1997;899-903.
4. De Boer R.J., Boucher C.A. Anti-CD4 therapy for AIDS suggested by mathematical models. Proc. R. Soc. Lond. B Biol. Sci. 263:1996;899-905.
5. De Boer R.J., Boucher C.A., Perelson A.S. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS. 12:1998;1567-1570.
6. Dornadula G., Zhang H., VanUitert B., Stern J., Livornese L. Jr., Ingerman M.J., Witek J., Kedanis R.J., Natkin J., DeSimone J., Pomerantz R.J. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. J. Am. Med. Assoc. 282:1999;1627-1632.
7. Elford H.L., van't Riet B. Inhibition of nucleoside diphosphate reductase by hydroxybenzohydroxamic acid derivatives. Pharmacol. Ther. 29:1985;239-254.
8. Elford H.L., Wampler G.L., van't Riet B. New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res. 39:1979;844-851.
9. Fraternale A., Tonelli A., Casabianca A., Chiarantini L., Schiavano G.F., Celeste A.G., Magnani M. New treatment protocol including lympholytic and antiretroviral drugs to inhibit murine AIDS. J. Acquir. Immune Defic. Syndr. 23:2000;107-113.
10. Freireich E.J., Gehan E.A., Rall D.P., Schmidt L.H., Skipper H.E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50:1966;219-244.
11. Gao W.Y., Cara A., Gallo R.C., Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA. 90:1993;8925-8928.
12. Gao W.Y., Johns D.G., Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol. Pharmacol. 46:1994;767-772.
13. Giacca M., Zanussi S., Comar M., Simonelli C., Vaccher E., De Paoli P., Tirelli U. Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. J. Infect. Dis. 174:1996;204-209.
14. Giorgi J.V., Liu Z., Hultin L.E., Cumberland W.G., Hennessey K., Detels R. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J. Acquir. Immune Defic. Syndr. 6:1993;904-912.
15. Klinman D.M., Morse H.C. Characteristics of B cell proliferation and activation in murine AIDS. J. Immunol. 142:1989;1144-1149.
16. Lee R., Beauparlant P., Elford H., Ponka P., Hiscott J. Selective inhibition of l kappaB alpha phosphorylation and HIV-1 LTR-directed gene expression by novel antioxidant compounds. Virology. 234:1997;277-290.
17. Lori F. Hydroxyurea and HIV: 5 years later - from antiviral to immune-modulating effects. AIDS. 13:1999;1433-1442.
18. Lori F., Lisziewicz J. Role of immune modulation in primary HIV infection. J. Biol. Regul. Homeost. Agents. 14:2000;45-48.
19. Lori F., Malykh A., Cara A., Sun D., Weinstein J.N., Lisziewicz J., Gallo R.C. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science. 266:1994;801-805.
20. Lori F., Malykh A.G., Foli A., Maserati R., De Antoni A., Minoli L., Padrini D., Degli A.A., Barchi E., Jessen H., Wainberg M.A., Gallo R.C., Lisziewicz J. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res. Hum. Retroviruses. 13:1997;1403-1409.
21. Maserati R. Hydroxyurea in the treatment of HIV-1 infection: toxicity and side effects. J. Biol. Regul. Homeost. Agents. 13:1999;181-185.
22. Mayhew C., Oakley O., Piper J., Hughes N.K., Phillips J., Birch N.J., Elford H.L., Gallicchio V.S. Effective use of ribonucleotide reductase inhibitors (Didox and Trimidox) alone or in combination with didanosine (ddI) to suppress disease progression and increase survival in murine acquired immunodeficiency syndrome (MAIDS). Cell. Mol. Biol. (Noisy-le-grand). 43:1997;1019-1029.
23. Mayhew C.N., Phillips J.D., Greenberg R.N., Birch N.J., Elford H.L., Gallicchio V.S. In vivo and in vitro comparison of the short-term hematopoietic toxicity between hydroxyurea and trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity. Stem Cells. 17:1999;345-356.
24. Meyerhans A., Vartanian J.P., Hultgren C., Plikat U., Karlsson A., Wang L., Eriksson S., Wain-Hobson S. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J. Virol. 68:1994;535-540.
25. Moore R.D., Keruly J.C., Chaisson R.E. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS. 15:2001;617-620.
26. Morse H.C., Chattopadhyay S.K., Makino M., Fredrickson T.N., Hugin A.W., Hartley J.W. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model for AIDS. AIDS. 6:1992;607-621.
27. Mosier D.E. Small animal models for acquired immune deficiency syndrome (AIDS) research. Lab. Anim. Sci. 46:1996;257-265.
28. Pace G.W., Leaf C.D. The role of oxidative stress in HIV disease. Free Radic. Biol. Med. 19:1995;523-528.
29. Palamara A.T., Garaci E., Rotilio G., Ciriolo M.R., Casabianca A., Fraternale A., Rossi L., Schiavano G.F., Chiarantini L., Magnani M. Inhibition of murine AIDS by reduced glutathione. AIDS Res. Hum. Retroviruses. 12:1996;1373-1381.
30. Perno C.F., Cooney D.A., Gao W.Y., Hao Z., Johns D.G., Foli A., Hartman N.R., Calio R., Broder S., Yarchoan R. Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Blood. 80:1992;995-1003.
31. Rauko P., Romanova D., Miadokova E., Macakova K., Novotny L., Elford H.L., Szekeres T. DNA-protective activity of new ribonucleotide reductase inhibitors. Anticancer Res. 17:1997;3437-3440.
32. Rutschmann O.T., Vernazza P.L., Bucher H.C., Opravil M., Ledergerber B., Telenti A., Malinverni R., Bernasconi E., Fagard C., Leduc D., Perrin L., Hirschel B. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. AIDS. 14:2000;2145-2151.
33. Shafer R.W., Winters M.A., Palmer S., Merigan T.C. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann. Intern. Med. 128:1998;906-911.
34. Stevenson M., Stanwick T.L., Dempsey M.P., Lamonica C.A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9:1990;1551-1560.
35. Szekeres T., Fritzer M., Strobl H., Gharehbaghi K., Findenig G., Elford H.L., Lhotka C., Schoen H.J., Jayaram H.N. Synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia HL-60 cells. Blood. 84:1994a;4316-4321.
36. Szekeres T., Gharehbaghi K., Fritzer M., Woody M., Srivastava A., van't Riet B., Jayaram H.N., Elford H.L. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemother. Pharmacol. 34:1994b;63-66.
37. Thelander L., Reichard P. Reduction of ribonucleotides. Annu. Rev. Biochem. 48:1979;133-158.
38. Tihan T., Elford H.L., Cory J.G. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime. Adv. Enzyme Regul. 31:1991;71-83.
39. Ussery M.A., Wood O.L., Broud D.D., Bacho M.A., Kunder S.C., Vona S.F., Nielsen C.J., Elford H.L. Didox, a novel ribonucleotide reductase inhibitor, is more active than hydroxyurea in HIV-infected HuPBMC SCID mice. Antiviral Ther. 4:(Suppl. 1):1999;12. Abstract.
40. Vigouroux C., Gharakhanian S., Salhi Y., Nguyen T.H., Adda N., Rozenbaum W., Capeau J. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab. 25:1999;383-392.
41. Zinkernagel R.M., Hengartner H. T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Immunol. Today. 15:1994;262-268.